A Multidisciplinary Roadmap for an Oral Therapeutic to Neutralize Uremic Toxins in Chronic Kidney Disease

Chronic Kidney Disease (CKD) poses a significant global health burden, primarily due to the accumulation of cytotoxic uremic toxins. Conventional renal replacement therapies, including dialysis, are invasive, resource-intensive, and exhibit limited efficacy in clearing protein-bound toxins. This manuscript delineates a conceptual framework for an innovative oral therapeutic aimed at neutralizing uremic toxins in the systemic circulation through competitive binding and facilitated clearance. Leveraging AI-driven medicinal chemistry, nanotechnology, and systems biology, we propose a multi-component formulation encapsulated in an advanced oral delivery system. This platform integrates AI-optimized active pharmaceutical ingredients (APIs) with nanoparticle carriers to address unmet needs in CKD management. The proposed therapeutic seeks to provide a non-invasive, efficacious, and cost-effective alternative to dialysis, potentially enhancing patient outcomes and quality of life. Herein, we elucidate the scientific rationale, formulation strategy, development roadmap, and requisite engineering and mathematical models for translational advancement. This revised edition incorporates refined molecular targets, APIs, chemical mechanisms, and quantitative analyses, emphasizing empirical validation requirements and ensuring scientific rigor through evidence-based support.